Company Overview - CryoPort expects revenues to improve as the year progresses, driven primarily by the Life Sciences Products group [1] - The stock has recently seen a significant increase of 26.7%, closing at $7.03, following a period of 47.6% loss over the past four weeks [2] Stock Performance - The recent stock price increase was accompanied by higher-than-average trading volume, indicating strong investor interest [2] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive sentiment among analysts [2] Earnings Estimates - The consensus EPS estimate for CryoPort has remained unchanged over the last 30 days, indicating stability in earnings expectations [3] - Trends in earnings estimate revisions are correlated with near-term stock price movements, suggesting that future performance should be monitored closely [7] Industry Context - CryoPort operates within the Zacks Transportation - Services industry, which includes other companies like Despegar.com [6] - Despegar.com has a Zacks Rank of 1 (Strong Buy) and is expected to report a quarterly loss of $0.36 per share, reflecting a year-over-year change of +14.3% [4][5]

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnershi ...

Core Viewpoint - The Schall Law Firm is investigating Cryoport, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1]. Group 1 - The investigation is aimed at protecting the rights of investors who may have suffered losses due to the company's actions [1]. - Shareholders are encouraged to participate in the investigation if they have experienced financial losses [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2].

Cryoport, Inc. (NASDAQ:CYRX) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President-Corporate Development and Investor Relations Conference Call Participants Matt Stanton – Jefferies Philip Song – Leerink Partners Lucas Baranowski – UBS David Larsen – BTIG Paul Knight ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (St ...

®2024 CRYOPORT, INC. Condensed Consolidated Statements of Operations (unaudited) | 16 March 31, $ (18,895) $ 46 | 17 Cryoport Enabling the Future of Medicine Increased by 21 trials (net) over Q1 2023 | --- | --- | --- | --- | --- | --- | --- | --- | |---------|-----------|-----------|-----------|-----------|-----------|-----------|-----------| | 350 | 609 | 652 | 675 | 600 | 609 | 652 | 675 | | 300 | | | | 500 | | | | | 250 | | | | 400 | | | | | 200 | | | | 300 | | | | | 150 | | | | 200 | | | | | 100 | | | ...

Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results NASHVILLE, Tennessee, May 7, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024. Jerrell Shelton, CEO of Cryoport, commented, "For the first quarter, we continued to experience a difficult environment globally. Our quarterly results were disappointing, particularly for our Life Sciences Products. Ho ...

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be i ...

Cryoport, Inc. (NASDAQ:CYRX) Q4 2023 Earnings Call Transcript March 12, 2024 5:00 PM ET Company Participants Todd Fromer - IR, KCSA Strategic Communications Jerrell Shelton - CEO Mark Sawicki - Chief Scientific Officer Robert Stefanovich - CFO Thomas Heinzen - VP of Corporate Development and IR Conference Call Participants Puneet Souda - Leerink Partners David Saxon - Needham Tejas Savant - Morgan Stanley John Sourbeer - UBS David Larsen - BTIG Yuan Zhi - B. Riley Securities Paul Knight - KeyBanc Operator G ...

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -59.38%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.Over the last four quarters, the company has surpassed consens ...